TCR2

About:

TCR2 is a discovery stage pharmaceutical company that developed a unique proprietary TRuC™ platform.

Website: http://www.tcr2.com/

Top Investors: Mirae Asset, Alexandria Venture Investments, Hillhouse Investment, Cathay Capital, MPM Capital

Description:

TCR2 is a discovery stage pharmaceutical company focused on engineering T cells for cancer therapy. The company's vast expertise in T cell engagement and a deep understanding of T cell receptor biology enabled the creation of a novel first-in-class approach that is highly differentiated from CAR-T cells and from T cells engineered to express defined TCR alpha/beta chains. TCR2 was founded by Dr. Patrick Baeuerle and MPM Capital. It has scientific operations in Kendall Square, Cambridge, Massachusetts to leverage best-in-class technologies and nucleate top-tier academic laboratories around the world.